Backed by Research.
Built for Results.

This randomized, placebo-controlled human trial investigated the effects of exogenous β-hydroxybutyrate monoester (BHB) on iron metabolism in people with newly diagnosed prediabetes. Over a 4-week period, daily BHB supplementation significantly reduced serum ferritin and increased total antioxidant capacity. These shifts suggest that BHB may help regulate iron homeostasis and lower oxidative stress—factors strongly linked to metabolic dysfunction. This adds a new dimension to ketone-based therapies beyond glucose management.

This conceptual framework outlines a “two-engine” system for optimizing cellular energy: the ketone engine for base-load power and the glucose engine for surge capacity. Researchers propose that ketone metabolism serves as a clean-burning fuel, reducing oxidative stress and enhancing mitochondrial efficiency. Meanwhile, glucose operates as a rapid-response booster engine. This model may inform future metabolic therapies that prioritize ketone-based energy for stable, long-term cellular performance while using glucose strategically for acute demands.

3‑Hydroxybutyrate (3HB) is one of the main ketone bodies produced by the liver during fasting or ketogenic diets. In a study using genetically diabetic mice, researchers evaluated whether increasing circulating 3HB could improve glycaemic control. They found that oral supplementation of a 3HB precursor lowered fasting blood glucose, improved glucose tolerance and reduced insulin resistance. Mechanistically, 3HB acted through the hydroxycarboxylic acid receptor 2 (HCAR2) to raise intracellular Ca2+ and cyclic AMP (cAMP) levels, activating protein kinase A and ultimately inhibiting phosphorylation of the nuclear receptor PPARγ at Ser273—a modification linked with insulin resistance. Genes downstream of PPARγ showed improved expression, and treated mice showed lower HOMA‑IR scores and improved metabolic profiles. These findings suggest that elevating circulating 3HB may be a practical strategy for improving insulin sensitivity in type 2 diabetes.

This clinical review highlights ketones as a promising therapy for traumatic brain injury (TBI) and stroke. By bypassing glucose metabolism, reducing inflammation, and supporting mitochondrial function, ketones—particularly β-hydroxybutyrate (BHB)—may improve outcomes in acute and chronic brain injury. Human and animal studies suggest benefits in reducing neuronal loss, improving energy availability, and enhancing recovery, though more clinical trials are needed. Ketone esters and ketogenic strategies could play a pivotal role in brain trauma care.

This study reveals a novel mechanism by which exogenous ketones lower blood glucose: by reducing the availability of the amino acid L-alanine, a key substrate for gluconeogenesis. In a randomized crossover trial, healthy volunteers consumed a ketone ester drink with or without L-alanine. Ketosis significantly reduced glucose levels, but this effect was blunted when L-alanine was supplemented. The findings suggest that ketone-induced reductions in L-alanine limit the liver’s ability to produce glucose, offering a compelling metabolic explanation for ketones' glucose-lowering effects and reinforcing their therapeutic potential in type 2 diabetes.

This Ohio State University study explored whether a ketone-salt and caffeine supplement could enhance exercise and cognitive performance in healthy, non-keto-adapted adults. Twelve recreationally trained participants consumed either the supplement or water before cycling to exhaustion. The supplement raised ketone levels over twofold and significantly increased time to exhaustion by 8.3% and Wingate average power by 4.3%. No significant cognitive benefits were observed. The supplement was well tolerated, with no adverse GI events. These findings support the ergogenic use of ketone salts with caffeine for boosting high-intensity exercise performance.